Phaseline

Targets › GIPR

GIPR (Gastric inhibitory polypeptide receptor): drug programs, companies and trials

14 programs from 11 companies in 147 trials: 54 Phase 3, 40 Phase 2, 29 Phase 4, 24 Phase 1; Metabolic and endocrine, Cardiovascular, Other; next expected readout Nov 2026.

This is a receptor for GIP. The activity of this receptor is mediated by G proteins which activate adenylyl cyclase. (UniProt, P48546)

Open in Phaseline: the race on GIPR, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
Eli LillyTirzepatide (LY3298176)
Gastric inhibitory polypeptide receptor agonist; Glucagon-like peptide 1 receptor agonist
GIPR, GLP1RPhase 4Diabetes Mellitus, Type 2; Psoriatic Arthritis; Type 2 Diabetes; Psoriasis …Nov 2026
The Cleveland ClinicGLP-1 or GIP-based therapy
GLP-1 receptor agonist and/or GIP receptor agonist
GLP1R, GIPRPhase 4GLP - 1–
AmgenMaridebart cafraglutide (AMG 133)
GLP-1 receptor agonist and GIP receptor agonist (dual GLP-1/GIP receptor agonist)
GLP1R, GIPRPhase 3Type 2 Diabetes Mellitus (T2DM), Obesity, Overweight; Obesity; Obesity Disease; Obstructive Sleep Apnea …Nov 2026
Eli LillyRetatrutide
Glucagon receptor agonist; Glucagon-like peptide 1 receptor agonist; Gastric inhibitory polypeptide receptor agonist
GCGR, GLP1R, GIPRPhase 3Obesity; Type 2 Diabetes; Diabetes Mellitus, Type 2; Atherosclerotic Cardiovascular Disease (ASCVD) …Nov 2026
PfizerBerobenatide (PF-08653944, MET097)
Dual GLP-1R/GIPR agonist
GIPR, GLP1RPhase 3Obesity and Overweight; Obesity; Apnea; Overweight …Jan 2027
RocheEnicepatide (RO7795068)
Dual GLP-1/GIP receptor agonist
GLP1R, GIPRPhase 3Obesity; Obesity or Overweight; Healthy ParticipantsApr 2027
Viking TherapeuticsVK2735
GLP-1 and GIP dual agonist
GLP1R, GIPRPhase 3Weight Loss; Obese AdultsMay 2027
Novo NordiskZenagamtide
GLP-1/GIP receptor agonist
GLP1R, GIPRPhase 3Overweight; Type 2 DiabetesJun 2028
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical SchoolMazdutide (IBI362)
Triple GLP-1/GIP/glucagon receptor agonist
GLP1R, GIPR, GCGRPhase 3Dementia, MildAug 2029
Regeneron PharmaceuticalsOlatorepatide (HS-20094)
GLP-1 and GIP receptor agonist
GLP1R, GIPRPhase 2Overweight or ObesityNov 2026
RocheRO7795081
GLP-1/GIP receptor dual agonist
GIPR, GLP1RPhase 2Type 2 Diabetes Mellitus; Overweight; Healthy Volunteers; Renal ImpairmentDec 2026
Hudson BiotechRetatrutide (LY3437943)
Glucagon receptor agonist; Glucagon-like peptide 1 receptor agonist; Gastric inhibitory polypeptide receptor agonist
GCGR, GLP1R, GIPRPhase 2ObesityMar 2027
Vanderbilt University Medical CenterGIP(3-30)NH2
GIP receptor antagonist
GIPRPhase 2Postural Tachycardia Syndrome (POTS)May 2027
Novo NordiskNNC0480-0389
GIP receptor agonist
GIPRPhase 1OverweightJan 2027

Conditions

Obesity (41) Overweight (10) Diabetes Mellitus, Type 2 (5) Type 2 Diabetes (4) Obesity and Obesity-related Medical Conditions (4) Obesity or Overweight (3) Type 2 Diabetes Mellitus (3) Type 1 Diabetes (3) Overweight or Obesity (2) Metabolic Dysfunction-Associated Steatotic Liver Disease (2) Apnea (2) Obesity (Disorder) (2)

Modalities

protein or peptide (9), small molecule (4), mixed (1)

Companies

Eli Lilly (2) Roche (2) Novo Nordisk (2) Amgen (1) Regeneron Pharmaceuticals (1) Pfizer (1) The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School (1) The Cleveland Clinic (1) Viking Therapeutics (1) Vanderbilt University Medical Center (1) Hudson Biotech (1)

Related targets

GLP1R (12) GCGR (3)

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.